This section provides various financial ratios derived from the company's financial statements to help assess its performance and financial health. Below are Return on Equity, Net Profit Margin, Debt to Asset Ratio, Cash Ratio, Current Ratio for SYRE as of 2025-12-31.
| Financial Ratios | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2024-12-31 |
|---|---|---|---|---|
| Current Ratio | 1,325.349 | 1,090.47 | 648.734 | - |
| Cash Ratio | 146.07 | 140.245 | 98.314 | - |
| Debt to Asset Ratio | 8.041 | 9.81 | 15.415 | - |
| Net Profit Margin | -77.199 | -10.9 | -0.566 | -90.489 |
| Return on Equity | -6.712 | -2.457 | -0.072 | - |
Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics, Inc. (SYRE)